Most Read Articles
2 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, Yesterday
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Circulating unmetabolized folic acid ups risk of breast cancer

13 Sep 2020

The presence of unmetabolized folic acid (UMFA) in the circulation appears to increase the risk of breast cancer, results of a nested case-control study have shown.

“Folates found in natural foods are thought to protect against cancer,” the authors said. “However, folic acid, a synthetic form of folate used in supplements and fortified foods, may increase breast cancer risk if present in unmetabolized form in the circulation.”

This nested case-control study was conducted in a prospective cohort, in which 553 patients with invasive breast cancer, diagnosed before mandatory folic acid fortification of grain in the US in 1998, were individually matched to 1,059 controls.

Liquid chromatography mass spectrometry was used to measure serum UMFA as well as 5-methyltetrahydrofolate (5-mTHF) in stored samples. The latter was also corrected for storage degradation.

No association was found between serum UMFA and breast cancer risk. The proportion of women with detectable levels of UMFA was comparable between cases and controls (18 percent vs 20 percent; p=0.46). Two tag-single nucleotide polymorphisms in the promoter region of the folic acid-metabolizing gene also did not correlate with the risk.

On the other hand, a marginally significant inverse association was noted between 5-mTHFcorrected and breast cancer risk (odds ratio for the highest vs lowest quintile, 0.69, 95 percent confidence interval, 0.49–0.97; ptrend=0.08).

“These results apply to countries without mandatory folic acid food fortification,” the authors said. “Studies are needed in countries with mandatory fortification, where levels of UMFA are much higher than in our study.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, Yesterday
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.